| # | Title | Journal | Year | Citations |
|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
| 2 | Patient-derived tumour xenografts as models for oncology drug development | Nature Reviews Clinical Oncology | 2012 | 1,091 |
| 3 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials | Lancet Oncology, The | 2020 | 1,034 |
| 4 | Molecular characterization of human prostate carcinoma cell lines | Prostate | 2003 | 555 |
| 5 | Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers | Nature Genetics | 2017 | 423 |
| 6 | Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer | Clinical Cancer Research | 2012 | 405 |
| 7 | Mammary Gland ECM Remodeling, Stiffness, and Mechanosignaling in Normal Development and Tumor Progression | Cold Spring Harbor Perspectives in Biology | 2011 | 373 |
| 8 | Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience | Journal of Thoracic Oncology | 2015 | 357 |
| 9 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study | Journal of Thoracic Oncology | 2019 | 324 |
| 10 | Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | Annals of Oncology | 2018 | 243 |
| 11 | AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells | Cell Stem Cell | 2018 | 189 |
| 12 | RAS Mutations in Human Melanoma: A Marker of Malignant Progression | Journal of Investigative Dermatology | 1994 | 180 |
| 13 | Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. | Journal of Clinical Oncology | 1995 | 171 |
| 14 | Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer | Oncologist | 2015 | 151 |
| 15 | An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators | Journal of Thoracic Oncology | 2014 | 148 |
| 16 | A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins | Molecular Oncology | 2013 | 140 |
| 17 | The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma | Journal of the American Academy of Dermatology | 2016 | 133 |
| 18 | Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study | Lancet Oncology, The | 2015 | 124 |
| 19 | Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer | British Journal of Cancer | 2015 | 123 |
| 20 | Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts | | 2019 | 123 |
| 21 | The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer | PLoS ONE | 2013 | 106 |
| 22 | Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations | Clinical Cancer Research | 2016 | 99 |
| 23 | Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients | Blood | 2011 | 94 |
| 24 | Collagen architecture in pregnancy-induced protection from breast cancer | Journal of Cell Science | 2013 | 87 |
| 25 | Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer | Molecular Cancer Therapeutics | 2016 | 85 |
| 26 | Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base | Cancer | 2016 | 84 |
| 27 | Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer | Annals of Surgical Oncology | 2015 | 81 |
| 28 | Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer | Clinical Lung Cancer | 2014 | 76 |
| 29 | Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma | Journal of Urology | 2020 | 76 |
| 30 | An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer | Journal of Thoracic Oncology | 2016 | 71 |
| 31 | Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer | Breast | 2013 | 70 |
| 32 | Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy | Annals of Oncology | 2017 | 70 |
| 33 | Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade | Oncotarget | 2017 | 70 |
| 34 | Activation of Wnt signaling promotes olaparib resistant ovarian cancer | Molecular Carcinogenesis | 2019 | 68 |
| 35 | Predictive value of oncogenic driver subtype, programmed death‐1 ligand (PD‐L1) score, and smoking status on the efficacy of PD‐1/PD‐L1 inhibitors in patients with oncogene‐driven non–small cell lung cancer | Cancer | 2019 | 66 |
| 36 | Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study | Lancet Oncology, The | 2018 | 62 |
| 37 | Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis | Molecular and Cellular Biochemistry | 1999 | 61 |
| 38 | Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer | Clinical Cancer Research | 2013 | 61 |
| 39 | Responses to Crizotinib Can Occur in High-Level MET -Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations | Journal of Thoracic Oncology | 2017 | 61 |
| 40 | Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor | Seminars in Oncology | 2014 | 60 |
| 41 | New basal cell carcinoma susceptibility loci | Nature Communications | 2015 | 59 |
| 42 | Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment | Archives of Pathology and Laboratory Medicine | 2012 | 58 |
| 43 | Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes | Breast Cancer Research | 2009 | 57 |
| 44 | STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth | Oncotarget | 2014 | 57 |
| 45 | ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events | Journal of Thoracic Oncology | 2019 | 56 |
| 46 | Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines | Prostate | 2003 | 52 |
| 47 | Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes | Clinical Cancer Research | 2021 | 52 |
| 48 | From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development | Journal of the National Cancer Institute | 2013 | 51 |
| 49 | cMET Exon 14 Skipping: From the Structure to the Clinic | Journal of Thoracic Oncology | 2016 | 51 |
| 50 | Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study | British Journal of Cancer | 2009 | 50 |
